Recruiting studies: Castrate Sensitive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Phase 2 · 12 location(s) · Sun Pharmaceutical Industries Limited · NCT05422911 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · 195 location(s) · Alliance for Clinical Trials in Oncology · NCT06931340 Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-rec
Phase 2 · 3 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06654336 This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · 341 location(s) · Pfizer · NCT07028853 PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06652607 Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
NA · 1 location(s) · Paul Viscuse · NCT06429813 A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Phase 1 · 25 location(s) · Astellas Pharma Global Development, Inc. · NCT04729114 Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Janssen Research & Development, LLC · NCT06800313

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →